Jim Simons Stealth Bio Therapeutics Corp Transaction History

Renaissance Technologies LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.2 - $0.32 $16,435 - $26,296	82,175 Added 556.4%	96,944 $30,000
Q2 2022 Aug 12, 2022	SELL	$0.18 - $0.71 $5,761 - $22,725	-32,008 Reduced 68.43%	14,769 $4,000
Q1 2022 May 13, 2022	SELL	$0.49 - $0.9 $5,131 - $9,425	-10,473 Reduced 18.29%	46,777 $33,000
Q4 2021 Feb 11, 2022	SELL	$0.76 - $1.48 $7,468 - $14,543	-9,827 Reduced 14.65%	57,250 $48,000
Q3 2021 Nov 12, 2021	SELL	$1.17 - $1.58 $17,316 - $23,384	-14,800 Reduced 18.08%	67,077 $91,000
Q2 2021 Aug 13, 2021	SELL	$1.07 - $1.77 $855,431 - $1.42 Million	-799,469 Reduced 90.71%	81,877 $128,000
Q1 2021 May 13, 2021	BUY	$1.38 - $2.42 $432,191 - $757,900	313,182 Added 55.12%	881,346 $1.38 Million
Q4 2020 Feb 10, 2021	BUY	$1.27 - $1.62 $608,206 - $775,822	478,903 Added 536.52%	568,164 $849,000
Q3 2020 Nov 13, 2020	SELL	$1.32 - $2.23 $219,510 - $370,840	-166,296 Reduced 65.07%	89,261 $121,000
Q2 2020 Aug 13, 2020	BUY	$1.23 - $2.22 $157,141 - $283,620	127,757 Added 99.97%	255,557 $468,000
Q1 2020 May 14, 2020	BUY	$0.97 - $3.13 $123,966 - $400,014	127,800 New	127,800 $158,000

2.94K

Ticker MITO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,548,600
Description
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duche...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.